Proactive Investors - Run By Investors For Investors

ReNeuron receives approval from US authorities to kick off phase IIb stroke trial

Long-term data from the PISCES II trial earlier this year showed ReNeuron’s CTX cell therapy candidate has the potential to improve the disability of stroke patients
stroke tablets
This next trial will test the effect of the treatment on a much larger cohort of stroke patients

ReNeuron Group Plc (LON:RENE) has been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.

Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.

READ: ReNeuron boss 'delighted' with long-term stroke data

PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.

It will compare how many patients treated with either the CTX therapy or a placebo demonstrate a “clinically important improvement” on the Modified Rankin Scale – a measure of disability and dependence.

Data from the study is expected towards the end of 2019.

"We are delighted to have received regulatory approval to commence our first clinical trial in the US with our CTX cell therapy candidate for stroke disability,” said chief executive Olav Hellebø.

“No therapeutic interventions are currently available to improve motor function and quality of life for disabled stroke patients.

“This important clinical trial represents a further step towards potentially meeting that very significant unmet need and we look forward to initiating the study during the first half of next year.”

Progress made in first half

Thursday’s approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa.

A phase II trial of hRPC in the degenerative eye disease is due to get underway in the middle of 2018, alongside a phase II study in cone rod dystrophy.

Elsewhere, pre-clinical data of ReNeuron’s ExoPr0 exosome therapy candidate also showed it may have a “significant effect” in regulating cell growth and reducing cancer cell proliferation.

The company also thinks it could be used to target “multiple” other diseases but for the time being it will focus on cancer, and an initial clinical trial application is planned for 2019.

Well funded

ReNeuron recorded a loss of £9.6mln (2016: loss of £7.7mln) for the six months through to September 30

At the end of the period the AIM-quoted group had £45.3mln of cash and cash equivalents (31 March: £53.1mln).

“During the period, our therapeutic development programmes have continued to progress to plan,” added Hellebø.

“This progress positions us for the delivery of further significant clinical milestones across our therapeutic programmes during each of the next three years.”

View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

Related Articles

knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use